BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

Volver

Resultados 58 resultados LastUpdate Última actualización 22/09/2017 [17:59:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   Mostrar por página


COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING

NºPublicación: US2017266207A1 21/09/2017

Solicitante:
THE BRAIN HEALTH PROJECT INC [US]

Resumen de: US2017266207A1

The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.



traducir


 

BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASES, AND METHOD FOR DETECTION OF COGNITIVE DYSFUNCTION DISEASES USING THE BIOMARKER

NºPublicación: US2017269105A1 21/09/2017

Solicitante:
MCBI INC [JP]

Resumen de: US2017269105A1

The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.



traducir


 

ALZHEIMER'S DISEASE EARLY DIAGNOSIS AND/OR PROGNOSIS IN CIRCULATING IMMUNE CELLS BASED ON HEPARAN SULFATES AND/OR OF HEPARAN SULFATE SULFOTRANSFERASES

NºPublicación: WO2017158045A1 21/09/2017

Solicitante:
UNIV PARIS VAL DE MARNE [FR]
ASSIST PUBLIQUE - HOPITAUX DE PARIS [FR]

Resumen de: WO2017158045A1

The present invention relates to a method of prognosis and/or diagnosis of Alzheimer's disease by determining the level and/or cellular distribution of heparan sulfates (HS) and/or heparan sulfate sulfotransferases (HSSTs) from isolating circulating immune cells in said circulating immune cells.



traducir


 

DIAGNOSTIC AUTOANTIBODY PROFILES FOR THE DETECTION AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES

NºPublicación: US2017261514A1 14/09/2017

Solicitante:
NAGELE ROBERT G [US]
ROWAN UNIV [US]

Resumen de: US2017261514A1

The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient-specific neurodegenerative disease diagnostic autoantibody profiles.



traducir


 

BIOMARKERS IN NASAL EXHALED BREATH

NºPublicación: WO2017155975A1 14/09/2017

Solicitante:
CHICAGO REHABILITATION INST [US]
UNIV NORTHWESTERN [US]

Resumen de: WO2017155975A1

A method of diagnosing or assessing risk of a tauopathy in a person is disclosed. The method may comprise collecting a nasal sample of exhaled breath from the person's nose, analyzing the nasal sample to detect the presence of tau protein in the sample, and determining the concentration of tau protein in the nasal sample, wherein the tau protein concentration in the nasal sample indicates susceptibility to the tauopathy.



traducir


 

MONOCLONAL ANTIBODY AGAINST HUMAN TAU PROTEIN

NºPublicación: US2017260262A1 14/09/2017

Solicitante:
AJ ROBOSCREEN GMBH [DE]

Resumen de: WO2016041553A2

The invention relates to the monoclonal antibody 1G2, the hybridoma cell line H-1 G2 characterized by DSM ACC3248, and the epitope TPP comprising the amino acids tryptophan, proline, proline. The invention further relates to a method for producing a monoclonal antibody against a TAU protein fraction that is non-phosphorylated in positions T175 and/or T181 and/or T231. The invention also describes uses of the monoclonal antibody 1 G2 as well as an immunochemical detection system and the uses thereof. The invention finally describes the use of the immunochemical detection system for diagnosing Alzheimer's disease in humans.



traducir


 

METHOD FOR DETECTING AGGREGATE FORM OF AGGREGATE-FORMING POLYPEPTIDE

NºPublicación: US2017261521A1 14/09/2017

Solicitante:
PEOPLEBIO INC [KR]

Resumen de: US2017261521A1

The present invention relates to a method for detecting an aggregate form of an aggregate-forming polypeptide in a biosample, comprising the steps of: (a) spiking, in a biosample to be analyzed, (i) a monomeric or multimeric form of an aggregate-forming polypeptide, (ii) a hydrophobic deleted derivative of the aggregate-forming polypeptide, or (iii) a monomeric or multimeric form of the aggregate-forming polypeptide and a hydrophobic deleted derivative of the aggregate-forming polypeptide; (b) additionally forming the aggregate form of the aggregate-forming polypeptide by incubating the product of step (a); (c) making the product of step (b) come into contact with a binder-label in which a signal-generating label is coupled to a binder binding to the aggregate form of the aggregate-forming polypeptide; and (d) detecting a signal to be generated from the binder-label bound to the aggregate form of the aggregate-forming polypeptide.



traducir


 

PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE

NºPublicación: US2017260263A1 14/09/2017

Solicitante:
AXON NEUROSCIENCE SE [CY]

Resumen de: US2017260263A1

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.



traducir


 

Transgenic mice

NºPublicación: AU2016222909A1 14/09/2017

Solicitante:
WILLIAM PATERSON UNIV OF NEW JERSEY

Resumen de: AU2016222909A1

The present invention provides a transgenic mouse and an animal model that is used to assay for the inhibition or activation of the Cnr2 gene and methods for screening drugs to treat or prevent psychosis, anxiety, depression, autism disorders, drug addiction, Parkinson's disease and/or Alzheimer's disease, multiple sclerosis, inflammation, stroke, osteoporosis, scleroderma or cancer.



traducir


 

DETECTION OF NEURODEGENERATIVE DISEASES

NºPublicación: WO2017153922A2 14/09/2017

Solicitante:
AMONETA DIAGNOSTICS SAS [FR]
JPT PEPTIDE TECH GMBH [DE]
CNRS - CENTRE NAT DE LA RECH SCIENT [FR]
UNIVERSIT\u00C9 DE STRASBOURG [FR]

Resumen de: WO2017153922A2

The present invention relates to novel compounds, their uses as biomarker, and/or methods including a non-invasive in vitro method using this biomarker, for diagnosing or monitoring the development or the progression of Alzheimer's disease (AD) or a disease or disorder associated with β-amyloid peptide (Aβ) deposition or tau hyperphosphorylation or a disease or disorder characterized by a proteinopathy implicating abnormalities in protein kinase C (PKC).



traducir


 

NON-HUMAN ANIMAL HAVING DYSTROPHY CAUSED BY PROTEIN AGGREGATION

NºPublicación: WO2017150566A1 08/09/2017

Solicitante:
SMC ASSET INC [JP]

Resumen de: WO2017150566A1

The present invention provides a model animal for establishing an effective treatment for protein aggregate diseases typified by Alzheimer's disease and the like. More specifically, the present invention provides the following. (A) A non-human animal having dystrophy caused by protein aggregation, in which the dystrophy caused by protein aggregation is induced by protein misfolding, and the dystrophy is facilitated; and (B) a method of preparing a non-human animal having dystrophy caused by protein aggregation, including the following steps (1) and (2): (1) protein misfolding is induced in a non-human animal to bring about dystrophy caused by protein aggregation in the non-human animal; and (2) a treatment of facilitating dystrophy caused by protein aggregation is carried out on the non-human animal.



traducir


 

ALZHEIMER'S DISEASE DIAGNOSTIC METHOD USING SIGNAL PEPTIDE AS INDEX

NºPublicación: WO2017150680A1 08/09/2017

Solicitante:
TOAGOSEI CO LTD [JP]
NAT UNIV CORP NAGOYA UNIV [JP]

Resumen de: WO2017150680A1

This method assists in the detection of Alzheimer's disease and involves determining the profile of signal peptides contained in a bodily fluid derived from a subject being examined, and comparing said determined signal peptide profile of the subject being examined with the profile of signal peptides in the bodily fluid derived from a pre-determined healthy subject. Further, this method is characterized in that a difference at a specific molecular weight between the signal peptide profile of the subject being examined and the signal peptide profile of the healthy subject is associated with the subject being examined suffering from or developing Alzheimer's disease.



traducir


 

METHOD AND A KIT FOR DETECTING A COMBINATION OF MARKERS FROM LIVER-DERIVED PLASMA EXTRACELLULAR VESICLES (PEV)

NºPublicación: WO2017149206A1 08/09/2017

Solicitante:
EVEXYS BIOTECH OY [FI]

Resumen de: WO2017149206A1

The present invention is directed to a method and a kit for detecting a combination of markers from plasma extracellular vesicles, wherein said markers are related to Alzheimer's disease, schizophrenia, depression, melanoma, breast cancer, cancer survival,drug-induced immune suppression, allergy or cancer relapse. Among the markers relating to Alzheimer's disease are MMP-2, MMP-3, MMP-13,TIMP-1,TIMP-2, FGF-6,ICAM-1, IGFBP-6, MIP-β, and VEGF.



traducir


 

BIOMATERIALS FOR NEURONAL IMPLANTS AND USE OF SAID BIOMATERIALS IN THE DIAGNOSIS AND THERAPY OF NEURONAL DISEASES

NºPublicación: US2017252486A1 07/09/2017

Solicitante:
ALBERT-LUDWIGS-UNIVERSITAT FREIBURG [DE]

Resumen de: US2017252486A1

The present invention relates to a neural implant comprising a biomaterial having an outer surface with a stochastic nanoroughness (Rq), and the application of said stochastic nanoroughness in the diagnosis and/or treatment of a neurological disorder, such as, for example, Parkinson's disease, Alzheimer's disease, glioblastoma and/or for disrupting and/or preventing glial scars in the context of mammalian mechanosensing ion channels selected from the family of PIEZO-1 and PIEZO-2 ion channels.



traducir


 

BIOMARKERS IN NASAL EXHALED BREATH

NºPublicación: US2017254817A1 07/09/2017

Solicitante:
CHICAGO REHABILITATION INST [US]
UNIV NORTHWESTERN [US]

Resumen de: US2017254817A1

A method of diagnosing or assessing risk of a tauopathy in a person is disclosed. The method may comprise collecting a nasal sample of exhaled breath from the person's nose, analyzing the nasal sample to detect the presence of tau protein in the sample, and determining the concentration of tau protein in the nasal sample, wherein the tau protein concentration in the nasal sample indicates susceptibility to the tauopathy.



traducir


 

METHOD FOR ENRICHING CNS-DERIVED EXOSOMES

NºPublicación: JP2017525976A 07/09/2017

Resumen de: WO2015200851A1

The present invention relates to a method for enriching CNS-derived exosomes from a biological fluid such as blood, serum, plasma, or saliva. The method comprises: contacting a biological fluid containing CNS-derived exosomes with an anti-L1CAM antibody to form an immunocomplex, binding CNS-derived exosomes in the biological fluid to a solid phase through the immunocomplex; and separating the solid phase bound exosomes from the biological fluid to enrich the CNS-derived exosomes. Biomarkers from the CNS-derived exosomes can be measured for detecting a neurological disease, differentiating among different neurological diseases, monitoring disease progression or objectively assessing existing and future medical treatments.



traducir


 

DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET

NºPublicación: WO2017147114A1 31/08/2017

Solicitante:
BLANCHETTE ROCKEFELLER NEUROSCIENCES INST [US]

Resumen de: WO2017147114A1

Methods of detecting the signature of Alzheimer's disease before the clinical onset of the disease are disclosed, such as methods of diagnosing Mild Cognitive Impairment (MCI), monitoring the progress of MCI, and predicting the time to clinical onset of AD dementia. The methods use a Biomarker Severity Score, which corresponds to output signals of one or more biomarkers chosen from AD Index, Morphometric Imaging, and PKC Epsilon Biomarkers. Also disclosed are methods of screening for a compound useful for treating MCI or for preventing the clinical onset of AD dementia, as well as methods of evaluating or monitoring the therapeutic benefit of an agent for treating MCI or preventing the clinical onset of AD dementia.



traducir


 

DISRUPTION OF THE INTERACTION BETWEEN AMYLOID BETA PEPTIDE AND DIETARY LIPIDS

NºPublicación: WO2017147529A1 31/08/2017

Solicitante:
UNIV COLUMBIA [US]

Resumen de: WO2017147529A1

The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associated cognitive disorders, multiple system atrophy, and rare neuroaxonal dystrophies, such as Niemann-Pick type C disease (NPC) and Gaucher's disease comprising administering an inhibitor to disrupt the interaction between Αβ or αS and neuronal lipids. The invention further relates to assays for identifying agents that reduce interaction between Αβ or αS and neuronal lipids. Lastly, the invention relates to methods and compositions for intranasal administration of fatty acids or lipids containing fatty acid acyl chains of dietary lipids for promoting central nervous system health and/or prevention or treatment of neurodegenerative disorders.



traducir


 

N-11 TRUNCATED AMYLOID-BETA MONOCLONAL ANTIBODIES, COMPOSITIONS, METHODS AND USES

NºPublicación: JP2017149719A 31/08/2017

Resumen de: CA2498058A1

This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A.szlig.11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.



traducir


 

IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT

NºPublicación: US2017248616A1 31/08/2017

Solicitante:
AMYDIS DIAGNOSTICS INC [US]

Resumen de: US2017248616A1

Provided herein are compositions and methods useful for detection of amyloid related disorders in samples, such as human tissue, cell or body fluid. Use of the compositions and methods herein allows for the rapid, in vitro detection of amyloid accumulation, often before amyloid disorder symptoms are manifest or without introduction of foreign fluorophore molecules into a subject.



traducir


 

Humanized antibody against amyloid beta

NºPublicación: KR20170098978A 30/08/2017

Resumen de: CN103524617A

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.



traducir


 

METHOD FOR DETECTING AGGREGATE FORM OF AGGREGATE-FORMING POLYPEPTIDE

NºPublicación: CN107110872A 29/08/2017

Resumen de: WO2016088999A1

The present invention relates to a method for detecting an aggregate form of an aggregate-forming polypeptide in a biosample, comprising the steps of: (a) spiking, in a biosample to be analyzed, (i) a monomeric or multimeric form of an aggregate-forming polypeptide, (ii) a hydrophobic deleted derivative of the aggregate-forming polypeptide, or (iii) a monomeric or multimeric form of the aggregate-forming polypeptide and a hydrophobic deleted derivative of the aggregate-forming polypeptide; (b) additionally forming the aggregate form of the aggregate-forming polypeptide by incubating the product of step (a); (c) making the product of step (b) come into contact with a binder-label in which a signal-generating label is coupled to a binder binding to the aggregate form of the aggregate-forming polypeptide; and (d) detecting a signal to be generated from the binder-label bound to the aggregate form of the aggregate-forming polypeptide.



traducir


 

USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN

NºPublicación: CN107091931A 25/08/2017

Resumen de: WO2013066818A1

This disclosure relates to the use of anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels of alpha-synuclein in a blood plasma or CSF following administration to the test subject of an anti-alpha-synuclein antibody or antigen-binding fragment thereof, which can bind alpha-synuclein with sufficient activity to alter the net efflux of alpha-synuclein from brain to blood, or from brain to CSF.



traducir


 

Presence of Phosphorylated Tau Protein in the Skin of Neurodegenerative Disease and SCIS, SCC, and BCC

NºPublicación: US2017242042A1 24/08/2017

Solicitante:
NORMAN ROBERT A [US]
CATANO MARIA [MX]
RODRIGUEZ-LEYVA ILDEFONSO [MX]

Resumen de: US2017242042A1

The presence of misfolded proteins in the brain is the hallmark of neurodegenerative diseases. Protein aggregates could have systemic expression and might be found in several tissues including the skin. This demonstrates the presence of phosphorylated Tau (p-Tau) in the skin cells of patients with Alzheimer's Disease (AD). Antibodies against p-Tau (PHF, phosphorylated at S296 and AT8, phosphorylated at S202) were assayed in biopsied tissue from the retro-auricular area in 49 subjects: 20 with AD, 12 with nondegenerative dementia and 17 age-matched controls. Light and confocal microscopies were employed to localize Tau protein by immunohistochemistry and their presence in the skin was confirmed through Western blots. The skin biopsy taken from AD patients presented significantly higher levels of p-Tau (AT8: hyperphosphorylated at Ser 202) when compared both to control subjects and patients with non-degenerative dementia (p<0.001). This study demonstrates the presence of p-Tau in skin biopsies by immunoreactivity. This procedure could be used to support the clinical diagnosis of AD in living patients.



traducir


 

METHOD FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT

Nº publicación: US2017242040A1 24/08/2017

Solicitante:
BIOCROSS S L [ES]

Resumen de: US2017242040A1

The invention relates to methods for determining the likelihood that a patient with mild cognitive impairment develops Alzheimer's disease based on the determination of the levels of different metabolites, including amino acids, proteins and lipids. The invention also provides a method for diagnosing Alzheimer's disease or mild cognitive impairment in a subject based on the determination of the above metabolites.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver